Introduction {#tca12495-sec-0001}
============

Invasive mucinous adenocarcinoma (IMA) is uncommon in the lung, accounting for 2--10% of primary lung adenocarcinomas.[1](#tca12495-bib-0001){ref-type="ref"} Compared to other variants of lung adenocarcinoma, cases of IMA carry a poorer prognosis.[2](#tca12495-bib-0002){ref-type="ref"} A number of studies have linked IMA and *KRAS* mutations,[3](#tca12495-bib-0003){ref-type="ref"}, [4](#tca12495-bib-0004){ref-type="ref"}, [5](#tca12495-bib-0005){ref-type="ref"} and a lower prevalence of *EGFR* mutations and a higher prevalence of *KRAS*, *ALK*, and *HER2* mutations were recently reported in conjunction with IMA, as opposed to other invasive adenocarcinomas.[6](#tca12495-bib-0006){ref-type="ref"} To the best of our knowledge, reports of an association between IMA and *RET* fusion genes are rare.

Case report {#tca12495-sec-0002}
===========

On May 19, 2015, a 36‐year‐old Chinese man was admitted complaining of dyspnea and chest discomfort that had lasted approximately two months, unaccompanied by hemoptysis or low‐grade fever. No pertinent signs emerged during physical examination. The patient had generally enjoyed good health and had no history of smoking. All pulmonary function tests, as well as cranial magnetic resonance imaging, bone scan, and abdominal ultrasound, showed no obvious abnormalities. Serum levels of carcinoembryonic antigen, squamous cell carcinoma antigen, and neuron‐specific enolase were also within normal reference ranges.

Subsequently, a CT scan revealed a sizeable mass (diameter 9 cm) within the middle lobe of the right lung. Its border at the upper lobe was poorly demarcated, and two small nodules in the right upper and lower lobes were also identified (Fig [1](#tca12495-fig-0001){ref-type="fig"}). A benign condition was considered, because the largest mass was ill defined and had not changed in size after two months of observation. Although fibrobronchoscopy was performed on two occasions, the bronchial lumen was devoid of lesions or external impingement, and no malignancy was identified in exfoliative cytology. Results of a positron emission tomography‐computed tomography (PET‐CT) scan were also compatible with a benign process of the right middle lobe (standardized update value 1.4). The nodules of the right upper and lower lobes failed to abnormally retain concentrated tracer, and no metastases were encountered in regional lymph nodes or in other areas of the body.

![A chest computed tomography scan shows (**a**) a 9 cm diameter mass in the middle lobe of the right lung (boundary with the upper lobe unclear); and (**b**) small nodules in the upper and lower lobes of the right lung (arrows).](TCA-8-710-g002){#tca12495-fig-0001}

The middle lobe of the right lung and the small nodule in the right upper lobe were resected during video‐assisted thoracoscopy on June 3, 2015. The mediastinal lymph nodes were also removed, leaving the separate lower lobe nodule intact. Upon examination, the growths were rich in mucus and highly gelatinous. Microscopic sections confirmed IMA at both the middle and upper lobe sites of involvement and in subcarinal lymph nodes (hematoxylin and eosin staining) (Fig [2](#tca12495-fig-0002){ref-type="fig"}a). Subsequent *EGFR* genetic testing (genes 18, 19, 20, and 21) was negative. The same was true of *EML4‐ALK* genetic fusion testing.

![(**a**) Hematoxylin and eosin stained sections of the tumor: copious mucus production fills the alveolar spaces. (**b**) Serial computed tomography scans of the chest show that the size of the lower lobe lesion was essentially unchanged during chemotherapy. The diameter of this lesion was 5 mm on May 20, 2015, October 13, 2015, and June 16, 2016 (left to right, marked by arrows).](TCA-8-710-g001){#tca12495-fig-0002}

Because the right lower lobe lesion remained unchanged after four chemotherapeutic cycles of pemetrexed/cisplatin (Fig [2](#tca12495-fig-0002){ref-type="fig"}b), the molecular structure of the tumor was explored. Profiling of genetic mutations via next‐generation sequencing (OncoScreen TM 295 genes, Burning Rock Dx, Guangzhou, China) (Table [S1](#tca12495-supitem-0001){ref-type="supplementary-material"}) revealed a high proportion (\~67.3%) of *KIAA1468‐RET* fusion gene (Table [S2](#tca12495-supitem-0002){ref-type="supplementary-material"}). No other tumor‐related somatic mutations were detected. The patient has survived for 20 months postoperatively, free of tumor recurrence or metastasis.

Discussion {#tca12495-sec-0003}
==========

The *RET* gene is a proto‐oncogene located in the pericentromeric region of chromosome 10q11.2, which encodes a single‐pass transmembrane, RTK. *RET* rearrangement is newly recognized as an oncogenic mutation in adenocarcinoma of the lung. The *RET* gene encodes a receptor tyrosine kinase that is critical in neural crest development,[7](#tca12495-bib-0007){ref-type="ref"} binding with its ligand (i.e. extracellular signaling molecules of the glial cell line‐derived neurotropic factor family)[8](#tca12495-bib-0008){ref-type="ref"} to activate downstream pathways. Mutated *RET* genes are visible in a variety of cancers, such as hereditary medullary thyroid carcinoma of multiple endocrine neoplasia, but are seldom seen in normal lung tissue.[9](#tca12495-bib-0009){ref-type="ref"}, [10](#tca12495-bib-0010){ref-type="ref"} To date, over seven *RET* fusion partner genes have been identified: *KIF5B*, the most common fusion partner gene with more than 10 variations; *CCDC6*; *CUX1*; *TRIM33*; *NCOA4*; *KIAA1468*; and *KIAA1217*. The RET tyrosine kinase in particular is preserved in all fusions and each RET partner protein contains a coiled‐coil domain, which is believed to promote ligand‐independent dimerization and constitutive activation of RET. Therefore*, KIAA1468‐RET,* which was detected in our case, is preserved in the RET tyrosine kinase. This phenomenon has been documented in close succession by several sources, all conceding that the *RET* fusion gene is a new key virulence mutation in lung cancer.[10](#tca12495-bib-0010){ref-type="ref"}, [11](#tca12495-bib-0011){ref-type="ref"}, [12](#tca12495-bib-0012){ref-type="ref"}, [13](#tca12495-bib-0013){ref-type="ref"} Cumulative data at present indicate that \~1.3% of patients with lung cancer harbor *RET* fusion genes, and nearly all corresponding tumors are adenocarcinomas.[14](#tca12495-bib-0014){ref-type="ref"} Although the current National Comprehensive Cancer Network guidelines (2014) clearly advise testing for *RET* fusion in patients with lung cancer,[15](#tca12495-bib-0015){ref-type="ref"} there are no targeted therapies directed specifically at *RET* as yet. Nevertheless, the following multi‐targeted agents may variably inhibit *RET* kinase activity: vandetanib (inhibiting *VEGFR*‐*2/3*, *EGFR*, and *RET*); sorafenib (inhibiting *VEGFR‐1/2, KIT, RET, CRAF,* and mutated *BRAF*); sunitinib (inhibiting *VEGFR‐2, KIT, RET,* and *PDGFR* alpha); and cabozantinib (inhibiting *VEGFR‐2, KIT, RET, MET, PLT‐1/3/4, TIE‐2* and *AXL*).[16](#tca12495-bib-0016){ref-type="ref"}, [17](#tca12495-bib-0017){ref-type="ref"} No clinical trials for molecular subtypes of *RET* fusion have been completed, but research is ongoing.

Our patient was satisfied with the surgery undertaken (i.e. resected right middle lobe, upper lobe nodule, and mediastinal lymph nodes), which confirmed IMA in both lobes of the lung and in the subcarinal nodes (pathologic stage T4N2M0). However, the residual disease in the right lower lobe proved refractory to chemotherapy, with no prospect of further surgical removal, radiation, or other options.

It is well known that targeted therapy may significantly prolong survival in patients with adenocarcinoma of the lung. Given current diagnostic guidelines, most clinicians are inclined to test for *EGFR* and *ALK* only, despite the fact that there are few targeted therapies focusing on *EGFR* or *ALK*. The results of both *EGFR* and *ALK* testing were negative in our patient, but next‐generation sequencing is capable of distinguishing more actionable genomic alterations than standard diagnostic methods.[18](#tca12495-bib-0018){ref-type="ref"} As genetic testing assumes greater importance in the clinical guidance of targeted therapy, the *RET* gene may increasingly become a potential target, enabling breakthrough treatments for patients with IMA of the lung.
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**Table S2** Next generation sequencing (OncoScreen TM 295 genes, Burning Rock Dx, Guangzhou, China): high proportion (\~67.3%) of *KIAA1468‐RET* fusion gene detected.
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